Endometrial Cancer Market to Register Sustainable Growth During the Forecast Period (2022-2032) – DelveInsight | Key Companies – GSK (Jemperli), Onconova (Narazaciclib), Karyopharm Therapeutics
The pipeline of Endometrial Cancer is very robust, many potential therapies are being investigated for the treatment of Endometrial Cancer, and it is safe to predict that the treatment space will experience a significant impact on the market during the forecast period.
DelveInsight’s “Endometrial Cancer Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Endometrial Cancer market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Endometrial Cancer market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Endometrial Cancer: An Overview
Endometrial cancer is a type of cancer that begins in the uterus. The uterus is the hollow, pear-shaped pelvic organ where fetal development occurs. It begins in the layer of cells that form the lining (endometrium) of the uterus. Endometrial cancer is sometimes called uterine cancer. Other types of cancer can form in the uterus, including uterine sarcoma, but they are much less common than endometrial cancer.
The most common type of endometrial cancer (type 1) grows slowly. It is most often found only inside the uterus. Type 2 is less common. It grows more rapidly and tends to spread to other parts of the body.
Endometrial Cancer Market Key Facts
-
The American Cancer Society estimates for cancer of the uterus in the United States for 2021 are: About 66,570 new cases of cancer of the body of the uterus (uterine body or corpus) will be diagnosed. About 12,940 women will die from cancers of the uterine body.
-
As per Cancer Research UK, there are around 9,400 new uterine cancer cases in the UK every year, that’s 26 every day (2015-2017). In females in the UK, uterine cancer is the 4th most common cancer, with around 9,500 new cases in 2017. Uterine cancer accounts for 5% of all new cancer cases in females in the UK (2017) and for 3% of all new cancer cases in females and males combined in the UK (2017).
-
According to the National Cancer Institute, approximately 3 in 100 women will be diagnosed with uterine cancer at some point in their lives. More than 80 percent of people with uterine cancer survive for five years or longer after receiving the diagnosis.
-
Some of the leading pharma giants developing drugs for the treatment of Endometrial Cancer include AstraZeneca, Karyopharm Therapeutics, Evergreen Therapeutics, and Incyte Corporation.
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Endometrial Cancer market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Endometrial Cancer market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Endometrial Cancer Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Endometrial Cancer Epidemiology Segmented by
-
Total Incident Cases of Endometrial Cancer in the 7MM (2019–2032)
-
Stage-specific Incident Cases of Endometrial Cancer in the 7MM (2019–2032)
-
Age-specific Cases of Endometrial Cancer in the 7MM (2019–2032)
Endometrial Cancer Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Endometrial Cancer market or expected to be launched during the study period. The analysis covers the Endometrial Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Endometrial Cancer pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Endometrial Cancer Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/endometrial-cancer-market
Endometrial Cancer Therapeutics Analysis
Over the past several decades, significant developments have been made in the endometrial cancer therapy market. Many monotherapies and combinations are in trial by major pharma and biotech giants. Companies across the globe are diligently working toward the development of novel treatment therapies, with a considerable amount of success over the years.
Several pharma and biotech giants are developing therapies to improve the Endometrial Cancer treatment scenario. GlaxoSmithKline is leading the therapeutics market with its Endometrial Cancer drug candidates in the mid to advanced stage of clinical development.
The Leading Companies in the Endometrial Cancer Therapeutics Market Include:
-
GlaxoSmithKline
-
Eisai Co Ltd
-
MedImmune
-
On Target Laboratories
-
Sutro Biopharma
-
Netris Pharma
-
AstraZeneca
-
Karyopharm Therapeutics
-
Evergreen Therapeutics
-
Incyte Corporation
And Many More
Endometrial Cancer Drugs Covered in the Report Include:
-
Lenvatinib (LENVIMA): Eisai Co Ltd
-
Dostarlimab: GlaxoSmithKline
-
Lynparza (Olaparib) +Imfinzi DuO-E: AstraZeneca
-
Selinexor: Karyopharm Therapeutics
-
EG-007: Evergreen Therapeutics
And Many Others
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/endometrial-cancer-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Endometrial Cancer Competitive Intelligence Analysis
4. Endometrial Cancer Market Overview at a Glance
5. Endometrial Cancer Disease Background and Overview
6. Endometrial Cancer Patient Journey
7. Endometrial Cancer Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Endometrial Cancer Treatment Algorithm, Current Treatment, and Medical Practices
9. Endometrial Cancer Unmet Needs
10. Key Endpoints of Endometrial Cancer Treatment
11. Endometrial Cancer Marketed Products
12. Endometrial Cancer Emerging Drugs and Latest Therapeutic Advances
13. Endometrial Cancer Seven Major Market Analysis
14. Attribute Analysis
15. Endometrial Cancer Market Outlook (In US, EU5, and Japan)
16. Endometrial Cancer Access and Reimbursement Overview
17. KOL Views on the Endometrial Cancer Market
18. Endometrial Cancer Market Drivers
19. Endometrial Cancer Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/endometrial-cancer-market
Other Trending Healthcare Reports By DelveInsight
The global Insulin Infusion Pumps Market was valued at USD 6.48 billion in 2021, growing at a CAGR of 8.69% during the forecast period from 2022 to 2027 to reach USD 10.68 billion by 2027. The insulin infusion pumps market is slated to witness prosperity owing to factors such as the growing prevalence of diabetes, increasing sedentary lifestyle, growing aging population base that is susceptible to the development of diabetes, and the growing focus on improving the safety and usability of insulin infusion pumps are further expected to result in the appreciable revenue growth during the forecast period (2022-2027).
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
 – DelveInsight | Key Companies – GSK (Jemperli), Onconova (Narazaciclib), Karyopharm Therapeutics){kind=link}